IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy

• Published in: Journal of clinical immunology Vol. 20; no. 1; pp. 77 - 82
• Main Authors: DE ALBUQUERQUE CAMPOS, R, NOTOMI SATO, M, DA SILVA DUARTE, A. J
• Format: Journal Article
• Language: English
• Published: New York, NY Kluwer/Plenum 2000; Springer Nature B.V
• Subjects: Adolescent; Adult; Antibodies, Anti-Idiotypic - blood; Antibodies, Anti-Idiotypic - classification; Biological and medical sciences; common variable immunodeficiency; Common Variable Immunodeficiency - immunology; Common Variable Immunodeficiency - therapy; Female; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunoenzyme Techniques; Immunoglobulin G - blood; Immunoglobulin G - immunology; Immunoglobulins, Intravenous - adverse effects; Immunopathology; Male; Medical sciences; Middle Aged; Human; Immunopathology; Immunoglobulins; Treatment; Intravenous administration; Antibody; Immunotherapy; Secondary effect; IgG; Complication; Predictive factor; Immune deficiency
• ISSN: 0271-9142; 1573-2592
• DOI: 10.1023/A:1006650812886

The current therapy for common variable immunodeficiency is based on the administration of intravenous immunoglobulin preparations which may cause severe adverse reactions. Some reports have associated these reactions with IgG anti-IgA antibodies, although this is not yet clear. We analyzed 20 sera from common variable immunodeficiency patients by an enzyme immunoassay to detect IgG anti-IgA and determine its subclass profile. Five patients presented high levels of these antibodies, all of them had IgG1, two had IgG2 and IgG4 and one had IgG3. Three of these five patients were receiving non IgA depleted intravenous immunoglobulin and had no severe adverse reactions. One patient had persisted with similar high levels of IgG anti-IgA during three years. Therefore, the IgG anti-IgA antibodies, regardless to their subclass profile in the common variable immunodeficiency patients sera do not seem to be associated with severe adverse reactions to intravenous immunoglobulins.